These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 27813127)

  • 1. Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases.
    Van der Schyf CJ
    Drug Dev Res; 2016 Dec; 77(8):458-468. PubMed ID: 27813127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifunctional drugs with different CNS targets for neuropsychiatric disorders.
    Van der Schyf CJ; Geldenhuys WJ; Youdim MB
    J Neurochem; 2006 Nov; 99(4):1033-48. PubMed ID: 17054441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.
    Hirao K; Pontone GM; Smith GS
    Neurosci Biobehav Rev; 2015 Feb; 49():157-70. PubMed ID: 25446948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neuropsychiatric manifestations in Parkinson's disease].
    Oikonomou E; Paparrigopoulos T
    Psychiatriki; 2015; 26(2):116-30. PubMed ID: 26197101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics in animal models of Alzheimer's and Parkinson's diseases.
    Sowell RA; Owen JB; Butterfield DA
    Ageing Res Rev; 2009 Jan; 8(1):1-17. PubMed ID: 18703168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A guide to management of neuropsychiatric manifestations of Parkinson's disease.
    Molina Ruiz RM; Evans AH; Velakoulis D; Looi JC
    Australas Psychiatry; 2016 Dec; 24(6):534-537. PubMed ID: 27329643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.
    Cummings J; Zhong K
    Clin Pharmacol Ther; 2015 Nov; 98(5):483-5. PubMed ID: 26206713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease.
    Cummings JL; Masterman DL
    J Clin Psychiatry; 1998; 59 Suppl 13():23-30. PubMed ID: 9771827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment.
    Chung JA; Cummings JL
    Neurol Clin; 2000 Nov; 18(4):829-46. PubMed ID: 11072263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of cognitive functions and neuropsychiatric symptoms between patients with Parkinson's disease dementia and Alzheimer's disease].
    Tang Y; Ji XJ; Xing Y; Zuo XM; Zhou AH; Jia JP
    Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2459-62. PubMed ID: 24300264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinesterase inhibitors: A new class of psychotropic compounds.
    Cummings JL
    Am J Psychiatry; 2000 Jan; 157(1):4-15. PubMed ID: 10618007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Alzheimer's and Parkinson's diseases networks using graph communities structure.
    Calderone A; Formenti M; Aprea F; Papa M; Alberghina L; Colangelo AM; Bertolazzi P
    BMC Syst Biol; 2016 Mar; 10():25. PubMed ID: 26935435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer's and Parkinson's diseases.
    Egensperger R; Kösel S; Schnopp NM; Mehraein P; Graeber MB
    Neuropathol Appl Neurobiol; 1997 Aug; 23(4):315-21. PubMed ID: 9292870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychiatric symptoms of dementia: are pharmacological treatments effective and safe?
    Ford AH
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):4. PubMed ID: 24876187
    [No Abstract]   [Full Text] [Related]  

  • 15. Cognitive, affective, and psychiatric features of Parkinson's disease.
    Barbas NR
    Clin Geriatr Med; 2006 Nov; 22(4):773-96, v-vi. PubMed ID: 17000335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for the early detection of Parkinson's and Alzheimer's disease.
    Berg D
    Neurodegener Dis; 2008; 5(3-4):133-6. PubMed ID: 18322370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
    Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
    Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Neuropsychiatric Symptoms on the Quality of Life of Subjects with Parkinson's Disease.
    Alvarado-Bolaños A; Cervantes-Arriaga A; Rodríguez-Violante M; Llorens-Arenas R; Calderón-Fajardo H; Millán-Cepeda R; Leal-Ortega R; Estrada-Bellmann I; Zuñiga-Ramírez C
    J Parkinsons Dis; 2015; 5(3):541-8. PubMed ID: 26406134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Effective Method to Identify Shared Pathways and Common Factors among Neurodegenerative Diseases.
    Li P; Nie Y; Yu J
    PLoS One; 2015; 10(11):e0143045. PubMed ID: 26575483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.
    Cilento EM; Jin L; Stewart T; Shi M; Sheng L; Zhang J
    J Neurochem; 2019 Nov; 151(4):397-416. PubMed ID: 30474862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.